Press Releases

In UniCAR technology, the T-cell (blue) binds to the tumor cell (red) via an artificially generated link. The immune response can be controlled by the dosage of the short-lived link. (c) HZDR / Sahneweiß / Kjpargeter, Freepik

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and the National Center for Tumor...

In the future, doctors will have more time to decide on the best therapy for treating patients with acute myeloid leukemia. (c) Uniklinikum Dresden/Marc Eisele

The diagnosis of acute myeloid leukemia (AML) was previously considered a medical emergency...

(c) NCT Heidelberg / Philip Benjamin

Press release of the NCT Heidelberg Cancer patients are particularly at risk for infections...

(c) Janosch Deeg/DKFZ

Scientists from the Biomedical Research Foundation of the Academy of Athens (Greece), the Institute...

View into tumor tissue of malignant melanoma: The enzyme caspase 8 (dark red dots) accumulates in the nuclei of the cancer cells and activates the cell survival mechanism, which is fatal for patients. (c) Institute of Pharmacology University of Bern

Researchers of the Carl Gustav Carus University Hospital Dresden at the National Center for Tumor...

The first patient treated with CAR-T cells at the NCT/UCC Dresden with the Early Clinical Trial Unit team (from right to left: Prof. Martin Bornhäuser, Dr. Martin Wermke, Dr. Raphael Teipel, Max Langner) Source: ECTU Dresden

National Center for Tumor Diseases Dresden begins several trials for new customized cancer...

Prof. Michael Baumann, Chairman of the Board of the DKFZ, Minister President Michael Kretschmer, Carpenter Ralf Tober, Dr. Ulrich Breuer, Chief Financial Officer of the HZDR, Wilfried Winzer, Chief Financial Officer of the UKD, at the topping-out ceremony

Operating room of the future provides new perspectives in cancer surgery • Building concept focuses...

Displaying results 1 to 7 out of 8

1

2

>